GW Pharma gives Epidiolex update

GW Pharmaceuticals Plc expects to complete its US regulatory submission for Epidiolex, a drug for childhood epilepsy, in October. Provided the review is favourable the drug could be launched in 2018, the company said.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom